AstraZeneca: Obesity trials
The registry lists 52 Obesity studies with AstraZeneca as lead sponsor. 8 are open to participants now and 9 have results posted.
Phase 1 25Phase 2 19Phase 3 6Phase 4 1No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 DiabetesNot yet recruitingNCT07922330Phase 3
- A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234Not yet recruitingNCT07911514Phase 1
- A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes MellitusRecruitingNCT07784725Phase 3
- A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or OverweightRecruitingNCT07784270Phase 3
- A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes MellitusRecruitingNCT07776509Phase 3
- A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes MellitusRecruitingNCT07775404Phase 3
- A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy ParticipantsRecruitingNCT07723833Phase 1
- A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.RecruitingNCT07511205Phase 1
- A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes MellitusCompletedNCT03745937Phase 2Results posted
- A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes MellitusCompletedNCT03596177Phase 2Results posted
- A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.CompletedNCT03555994Phase 2Results posted
- A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese SubjectsTerminatedNCT01235741Phase 2Results posted
- Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With MetreleptinCompletedNCT00819234Phase 2Results posted
- Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight SubjectsCompletedNCT00673387Phase 2Results posted
- A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese PatientsCompletedNCT00500370Phase 2Results posted
- A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese SubjectsCompletedNCT00392925Phase 2Results posted
- Effect on Weight Loss of Exenatide Versus PlaceboCompletedNCT00375492Phase 3Results posted
- A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy ParticipantsActive, not recruitingNCT07534592Phase 1
- A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy ParticipantsCompletedNCT07444424Phase 1
- A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234CompletedNCT07220954Phase 1
- This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / OverweightActive, not recruitingNCT07017179Phase 2
- A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or ObesityActive, not recruitingNCT07013643Phase 1
- A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral FormulationsCompletedNCT06996886Phase 1
- A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy ParticipantsCompletedNCT06948747Phase 1
- A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female ParticipantsCompletedNCT06942936Phase 1
- A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With ObesityCompletedNCT06942923Phase 1
- A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs AloneCompletedNCT06862791Phase 2
- Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor AgonistCompletedNCT06851858Phase 2
- A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes MellitusCompletedNCT06703658Phase 1
- A Study in Participants With Obesity or Overweight With at Least One Weight-related ComorbidityCompletedNCT06595238Phase 2
- Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related ComorbidityCompletedNCT06579092Phase 2
- A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy ParticipantsCompletedNCT06555822Phase 1
- A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and OverweightActive, not recruitingNCT06151964Phase 1/2
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or ObeseCompletedNCT06132841Phase 1
- Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or ObeseCompletedNCT05511025Phase 1
- Chinese Multiple Dose Escalation (MDE) High Dose StudyCompletedNCT05437848Phase 1
- A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis PatientsCompletedNCT04483947Phase 1
- A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese ParticipantsCompletedNCT03625778Phase 1
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.CompletedNCT02760316Phase 1
- To Assess the Safety, Tolerability, Pharmacokinetics and Pharmakodynamics of AZD2820 After Multiple Ascending DosesTerminatedNCT01469923Phase 1
- Japanese Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic (PK) & Pharmacodynamic (PD) Study of AZD7687CompletedNCT01217905Phase 1
- To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of AZD8329CompletedNCT01207089Phase 1
- AZD7687 Multiple Ascending Dose StudyCompletedNCT01119352Phase 1
- Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose TissueCompletedNCT01096004Phase 1
- PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated PatientsCompletedNCT01020604
- European Study of Cardiovascular RiskCompletedNCT00882336
- Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight SubjectsCompletedNCT00785408Phase 2
- Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese SubjectsCompletedNCT00444561Phase 2
- A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese SubjectsCompletedNCT00402077Phase 2
- C-Reactive Protein (CRP) in Obese Diabetic WomenCompletedNCT00262548Phase 4
- A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese SubjectsCompletedNCT00189514Phase 2
- A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese SubjectsCompletedNCT00112021Phase 2